GlassScriptPhysician profile
Tracy A Bridges
NPI 1386749117
$364,257.02
in general payments reported to CMS, 2019-2025
43 companies · $81K in 2025
The $81K reported for 2025 was more than what 97% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45K · 2020: $24K · 2021: $37K · 2022: $29K · 2023: $59K · 2024: $89K · 2025: $81K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $207K · Food and Beverage: $12K · Travel and Lodging: $10K · Consulting Fee: $120 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $207,270.00 |
| Food and Beverage | $11,938.24 |
| Travel and Lodging | $10,324.85 |
| Consulting Fee | $119.76 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $257,126.47 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Regeneron Healthcare Solutions, INC. | $36,139.52 | 2019-2025 | Dupixent |
| Amgen INC. | $26,282.23 | 2021-2025 | Tezspire |
| Genzyme Corporation | $11,693.56 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $7,960.02 | 2020-2025 | Cuvitru, Glassia, Hyqvia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $7,512.50 | 2019-2025 | Ofev |
| Shire North American Group INC | $4,699.90 | 2019 | |
| Grifols USA, LLC | $2,734.67 | 2020-2025 | Xembify, Prolastin-C Liquid |
| Teva Pharmaceuticals USA, INC. | $1,871.71 | 2019-2022 | |
| Glaxosmithkline, LLC. | $1,768.95 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Genentech USA, INC. | $1,579.12 | 2020-2025 | Xolair |
| Octapharma USA, INC. | $862.47 | 2019-2021 | |
| Biocryst US Sales Co., LLC | $721.58 | 2022-2025 | Orladeyo |
| Pfizer INC. | $709.57 | 2019-2025 | |
| Csl Behring | $541.29 | 2019-2025 | Hizentra, Andembry, Haegarda |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $430.93 | 2019-2025 | |
| Leo Pharma INC. | $270.84 | 2022-2025 | Adbry, Anzupgo |
| Abbvie INC. | $268.09 | 2021-2025 | Rinvoq |
| Kaleo, INC. | $191.13 | 2019-2023 | Auvi-Q |
| Blueprint Medicines Corporation | $178.46 | 2023 | Ayvakit |
| Adma Biomanufacturing LLC | $119.76 | 2023-2025 | |
| Optinose US, INC. | $75.98 | 2019-2021 | |
| Pharming Healthcare, INC. | $69.07 | 2020-2025 | Ruconest |
| Alk-Abello, INC | $67.54 | 2020-2022 | |
| Incyte Corporation | $57.24 | 2024-2025 | Opzelura |
| Sunovion Pharmaceuticals INC. | $57.19 | 2019-2020 | |
| Ars Pharmaceuticals Operations, INC. | $46.69 | 2025 | Neffy |
| Dermavant Sciences, INC. | $43.37 | 2023-2024 | Vtama |
| Bio Products Laboratory USA, INC. | $42.51 | 2022 | |
| Cycle Pharmaceuticals INC | $30.19 | 2025 | Sajazir |
| Ionis Pharmaceuticals, INC. | $28.12 | 2025 | Dawnzera |
| Phathom Pharmaceuticals, INC. | $22.54 | 2024 | Voquezna |
| Horizon Therapeutics Plc | $22.32 | 2021 | |
| Lilly USA, LLC | $18.58 | 2024 | Taltz, Ebglyss |
| Sanofi-Aventis U.S. LLC | $12.91 | 2019 |
8 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracy Bridges listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.